Top

Journal of Neurology

Published in:

01-08-2019 | Parkinson's Disease | Original Communication

Real-world pharmacological treatment patterns of patients with young-onset Parkinson’s disease in Japan: a medical claims database analysis

Authors: Sachiko Kasamo, Masato Takeuchi, Masashi Ikuno, Yohei Kawasaki, Shiro Tanaka, Ryosuke Takahashi, Koji Kawakami

Published in: Journal of Neurology | Issue 8/2019

Abstract

Introduction

Young-onset Parkinson’s disease is reported to comprise 5–10% of all Parkinson’s disease cases; however, as physicians encounter a limited number of these patients, their treatment patterns are still unclear.

Methods

We performed a descriptive study using the large Japanese medical claims database to describe the epidemiology and real-world pharmacological treatment patterns of newly diagnosed patients with young-onset Parkinson’s disease. Patients aged 21–50 years in whom Parkinson’s disease was newly diagnosed between January 1, 2005 and March 31, 2016 were included. We excluded individuals with Parkinson’s-related diseases and those using antipsychotics to eliminate the possibility of drug-induced parkinsonism. The patients’ demographics, comorbidities, prescribing patterns, and changes in levodopa equivalent daily dose were analyzed.

Results

We identified 131 newly diagnosed young-onset Parkinson’s disease patients (median age, 44.2 years). The most common comorbidities were depression (23.7%), hypertension (23.7%), and insomnia (22.9%). Of these patients, 122 were prescribed antiparkinson drugs. During the study period, the proportion of patients who were prescribed dopamine agonists, levodopa, and anticholinergics were 77.1%, 44.3%, and 27.5%, respectively. Dopamine agonists (49.2%) were most commonly prescribed initially, followed by anticholinergics (23.8%), levodopa (19.7%), and others (4.1%). The levodopa equivalent daily dose increased steadily with longer disease duration.

Conclusions

Dopamine agonists were most frequently prescribed during the study period and were the initial treatment of choice. We also observed a change in levodopa equivalent daily dose over the disease course. This study provides a descriptive overview of real-world prescribing patterns in young-onset Parkinson’s disease patients.

Connolly BS, Lang AE (2014) Pharmacological treatment of Parkinson disease: a review. JAMA 311:1670–1683. https://doi.org/10.1001/jama.2014.3654 CrossRef

Mehanna R, Moore S, Hou JG et al (2014) Comparing clinical features of young onset, middle onset and late onset Parkinson’s disease. Parkinsonism Relat Disord 20:530–534. https://doi.org/10.1016/j.parkreldis.2014.02.013 CrossRefPubMed

Wickremaratchi MM, Ben-Shlomo Y, Morris HR (2009) The effect of onset age on the clinical features of Parkinson’s disease. Eur J Neurol 16:450–456. https://doi.org/10.1111/j.1468-1331.2008.02514.x CrossRefPubMed

Ferguson LW, Rajput AH, Rajput A (2016) Early-onset vs. late-onset Parkinson’s disease: a clinical-pathological study. Can J Neurol Sci 43:113–119. https://doi.org/10.1017/cjn.2015.244 CrossRefPubMed

Taniguchi A, Narita Y, Naito Y, Kuzuhara S (2008) An analysis of application form of Parkinson’s disease provided by the specific diseases treatment research program of Ministry of Health, Labour and Welfare of Japan. Rinsho Shinkeigaku 48:106–113. https://doi.org/10.5692/clinicalneurol.48.106 CrossRefPubMed

Kostić VS (2009) Treatment of young-onset Parkinson’s disease: role of dopamine receptor agonists. Parkinsonism Relat Disord 15:S71–S75. https://doi.org/10.1016/S1353-8020(09)70839-9 CrossRefPubMed

Mizuno Y (2012) An update on the management of juvenile and young-onset Parkinson’s disease. Future Neurol 7:581–593. https://doi.org/10.2217/fnl.12.59 CrossRef

Kimura S, Sato T, Ikeda S et al (2010) Development of a database of health insurance claims: standardization of disease classifications and anonymous record linkage. J Epidemiol 20:413–419. https://doi.org/10.2188/jea.je20090066 CrossRefPubMedPubMedCentral

Japan Medical Data Center (2018) Features of JMDC medical data. https://www.jmdc.co.jp/en/about/database.html. Accessed 01 Jan 2018

10.

Tomlinson CL, Stowe R, Patel S et al (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25:2649–2653. https://doi.org/10.1002/mds.23429 CrossRef

11.

Oeda T, Umemura A, Tomita S et al (2013) Clinical factors associated with abnormal postures in Parkinson’s disease. PLoS ONE 8:e73547. https://doi.org/10.1371/journal.pone.0073547 CrossRefPubMedPubMedCentral

12.

Wood SN, Pya N, Säfken B (2016) Smoothing parameter and model selection for general smooth models. J Am Stat Assoc 111:1548–1563. https://doi.org/10.1080/01621459.2016.1180986 CrossRef

13.

Leoni O, Martignoni E, Cosentino M et al (2002) Drug prescribing patterns in Parkinson’s disease: a pharmacoepidemiological survey in a cohort of ambulatory patients. Pharmacoepidemiol Drug Saf 11:149–157. https://doi.org/10.1002/pds.682 CrossRefPubMed

14.

Trifirò G, Savica R, Morgante L et al (2008) Prescribing pattern of anti-Parkinson drugs in Southern Italy: cross-sectional analysis in the years 2003–2005. Parkinsonism Relat Disord 14:420–425. https://doi.org/10.1016/j.parkreldis.2007.10.010 CrossRefPubMed

15.

Nakaoka S, Ishizaki T, Urushihara H et al (2014) Prescribing pattern of anti-Parkinson drugs in Japan: a trend analysis from 2005 to 2010. PLoS ONE 9:e99021. https://doi.org/10.1371/journal.pone.0099021 CrossRefPubMedPubMedCentral

16.

Yoritaka A, Shimo Y, Takanashi M et al (2013) Motor and non-motor symptoms of 1453 patients with Parkinson’s disease: prevalence and risks. Parkinsonism Relat Disord 19:725–731. https://doi.org/10.1016/j.parkreldis.2013.04.001 CrossRefPubMed

17.

Osaki Y, Morita Y, Kuwahara T et al (2011) Prevalence of Parkinson’s disease and atypical parkinsonian syndromes in a rural Japanese district. Acta Neurol Scand 124:182–187. https://doi.org/10.1111/j.1600-0404.2010.01442.x CrossRefPubMed

18.

Yamawaki M, Kusumi M, Kowa H, Nakashima K (2009) Changes in prevalence and incidence of Parkinson’s disease in Japan during a quarter of a century. Neuroepidemiology 32:263–269. https://doi.org/10.1159/000201565 CrossRefPubMed

19.

de Lau LML, Giesbergen PCLM, de Rijk MC et al (2004) Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam Study. Neurology 63:1240–1244. https://doi.org/10.1212/01.wnl.0000140706.52798.be CrossRefPubMed

20.

Barone P, Antonini A, Colosimo C et al (2009) The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord 24:1641–1649. https://doi.org/10.1002/mds.22643 CrossRefPubMed

21.

Simon KC, Chen H, Schwarzschild M, Ascherio A (2007) Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology 69:1688–1695. https://doi.org/10.1212/01.wnl.0000271883.45010.8a CrossRefPubMedPubMedCentral

22.

Bower JH, Maraganore DM, Peterson BJ et al (2006) Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: a case–control study. Neurology 67:494–496. https://doi.org/10.1212/01.wnl.0000227906.99570.cc CrossRef

23.

Park A, Stacy M (2009) Non-motor symptoms in Parkinson’s disease. J Neurol 256(Suppl):293–298. https://doi.org/10.1007/s00415-009-5240-1 CrossRefPubMed

24.

Todorova A, Jenner P, Ray Chaudhuri K (2014) Non-motor Parkinson’s: integral to motor Parkinson’s, yet often neglected. Pract Neurol 14:310322. https://doi.org/10.1136/practneurol-2013-000741 CrossRef

25.

Müller B, Larsen JP, Wentzel-Larsen T et al (2011) Autonomic and sensory symptoms and signs in incident, untreated Parkinson’s disease: frequent but mild. Mov Disord 26:65–72. https://doi.org/10.1002/mds.23387 CrossRefPubMed

26.

Mizuno Y, Shimoda S, Origasa H (2018) Long-term treatment of Parkinson’s disease with levodopa and other adjunctive drugs. J Neural Transm 125:35–43. https://doi.org/10.1007/s00702-016-1671-x CrossRefPubMed

27.

Lang AE (1984) Treatment of Parkinson’s disease with agents other than levodopa and dopamine agonists: controversies and new approaches. Can J Neurol Sci 11:210–220. https://doi.org/10.1017/S0317167100046436 CrossRefPubMed

28.

Spehlmann R, Stahl SM (1976) Dopamine acetylcholine imbalance in Parkinson’s disease. Possible regenerative overgrowth of cholinergic axon terminals. Lancet (London, England) 1:724–726. https://doi.org/10.1016/S0140-6736(76)93095-6 CrossRef

29.

Tarsy D (2006) Initial treatment of parkinson’s disease. Curr Treat Options Neurol 8:224–235. https://doi.org/10.1007/s11940-006-0013-y CrossRefPubMed

30.

Japanese Society of Neurology (2002) Parkinson’s disease treatment guideline 2002. Clin Neurol 42:421–494 (In Japanese)

31.

Japanese Society of Neurology (2018) Parkinson’s disease treatment guideline 2018. Igakushoin, Tokyo (In Japanese)

32.

Japanese Society of Neurology (2011) Parkinson’s disease treatment guideline 2011. Igakushoin, Tokyo (In Japanese)

33.

The National Institute for Health and Care Excellence (2006) Parkinson’ s disease in over 20s: diagnosis and management (CG35). In: Natl. Inst. Heal. Care Excell. https://www.nice.org.uk/guidance/cg35. Accessed 05 June 2017

34.

Rascol O, Brooks DJ, Korczyn AD et al (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med 342:1484–1491. https://doi.org/10.1056/NEJM200005183422004 CrossRef

35.

Holloway RG, Shoulson I, Fahn S et al (2004) Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 61:1044–1053. https://doi.org/10.1001/archneur.61.7.1044 CrossRefPubMed

36.

Guo Y-J, Liao Y-C, Lin C-H, Chang M-H (2014) Initial medication in patients of newly diagnosed Parkinson’s disease in Taiwan. PLoS ONE 9:e107465. https://doi.org/10.1371/journal.pone.0107465 CrossRefPubMedPubMedCentral

37.

Mullin S, Schapira A (2015) The genetics of Parkinson’s disease. Br Med Bull 114:39–52. https://doi.org/10.1093/bmb/ldv022 CrossRefPubMed

38.

Alcalay RN, Mirelman A, Saunders-Pullman R et al (2013) Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations. Mov Disord 28:1966–1971. https://doi.org/10.1002/mds.25647 CrossRefPubMed

39.

Brockmann K, Srulijes K, Pflederer S et al (2015) GBA-associated Parkinson’s disease: reduced survival and more rapid progression in a prospective longitudinal study. Mov Disord 30:407–411. https://doi.org/10.1002/mds.26071 CrossRefPubMed

40.

McLeod HL, Syvänen AC, Githang’a AC et al (1998) Ethnic differences in catechol O-methyltransferase pharmacogenetics: frequency of the codon 108/158 low activity allele is lower in Kenyan than Caucasian or South-west Asian individuals. Pharmacogenetics 8:195–199PubMed

41.

Bhidayasiri R, Hattori N, Jeon B et al (2015) Asian perspectives on the recognition and management of levodopa “wearing-off” in Parkinson’s disease. Expert Rev Neurother 15:1285–1297. https://doi.org/10.1586/14737175.2015.1088783 CrossRefPubMed

42.

The National Institute for Health and Care Excellence (2017) Parkinson’s disease in adults | Guidance and guidelines | NICE. https://www.nice.org.uk/guidance/ng71/chapter/Recommendations. Accessed 14 Jan 2019.

43.

Hattori N, Takeda A, Takeda S et al (2018) Rasagiline monotherapy in early Parkinson’s disease: a phase 3, randomized study in Japan. Parkinsonism Relat Disord 1:2. https://doi.org/10.1016/j.parkreldis.2018.08.024 CrossRef

44.

Ministry of Justice Stimulants Control Act (Japanese Law Translation). https://www.japaneselawtranslation.go.jp/law/detail/?id=2814&vm=04&re=01. Accessed 31 Mar 2019.

45.

Andersohn F, Garbe E (2009) Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists. Mov Disord 24:129–133. https://doi.org/10.1002/mds.22385 CrossRefPubMed

46.

Barone P, Poewe W, Albrecht S et al (2010) Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 9:573–580. https://doi.org/10.1016/S1474-4422(10)70106-X CrossRefPubMed

47.

Murata M, Horiuchi E, Kanazawa I (2001) Zonisamide has beneficial effects on Parkinson’s disease patients. Neurosci Res 41:397–399. https://doi.org/10.1016/S0168-0102(01)00298-X CrossRefPubMed

48.

Murata M (2004) Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson’s disease. Curr Pharm Des 10:687–693. https://doi.org/10.2174/1381612043453180 CrossRefPubMed

49.

Katsube J, Narabayashi H, Hayashi A et al (1994) Development of l-threo-DOPS, a norepinephrine precursor amino acid. Yakugaku Zasshi 114:823–846. https://doi.org/10.1248/yakushi1947.114.11_823 (In Japanese)CrossRefPubMed

50.

Lundbeck (2018) Nothera^® (droxidopa) capsules, Highlights of prescribing information. https://www.lundbeck.com/upload/us/files/pdf/Products/Northera_PI_US_EN.pdf. Accessed 01 Apr 2019.

51.

Rizzo G, Copetti M, Arcuti S et al (2016) Accuracy of clinical diagnosis of Parkinson disease: a systematic review and meta-analysis. Neurology 86:566–576. https://doi.org/10.1212/WNL.0000000000002350 CrossRefPubMed

Title: Real-world pharmacological treatment patterns of patients with young-onset Parkinson’s disease in Japan: a medical claims database analysis
Authors: Sachiko Kasamo
Masato Takeuchi
Masashi Ikuno
Yohei Kawasaki
Shiro Tanaka
Ryosuke Takahashi
Koji Kawakami
Publication date: 01-08-2019
Publisher: Springer Berlin Heidelberg
Keywords: Parkinson's Disease
Levodopa
Dopamine Agonist
Pramipexole
MAO-B Inhibitor
Published in: Journal of Neurology / Issue 8/2019
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-019-09360-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Real-world pharmacological treatment patterns of patients with young-onset Parkinson’s disease in Japan: a medical claims database analysis

Abstract

Introduction

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2019

A randomized controlled trial on the efficacy, safety, and pharmacokinetics of metformin in severe traumatic brain injury

Factors that predict diagnostic stability in neurodegenerative dementia

Relevance of anti-HNK1 antibodies in the management of anti-MAG neuropathies

Cortical microinfarcts in patients with multiple lobar microbleeds on 3 T MRI

Idiopathic acute high-tone sensorineural hearing loss accompanied by vertigo: vestibulo-cochlear artery syndrome? Consideration based on VEMP and vHIT

Head tremor at disease onset: an ataxic phenotype of cervical dystonia